New Delhi, Feb. 3 -- Mankind Pharma's net profit climbed 9.5% in the third quarter, missing estimates, as revenue increased, driven by domestic growth and consolidation of Bharat Serums and Vaccines Ltd (BSV), which it acquired in 2024.

The drugmaker's profit rose to Rs.414 crore in the three months ended December from Rs.378 crore a year earlier, the company said in a statement on Tuesday. Profit declined 20.4% sequentially. Revenue grew to Rs.3,567 crore.

A Bloomberg poll of 10 brokerages pegged Mankind's net profit at Rs.507 crore and revenue at Rs.3,607 crore. Ebitda was little changed at Rs.816 crore on-year, while the adjusted Ebitda margin contracted by 170 basis points to 25.9%.

"BSV growth initiatives are progressing well, wit...